Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription

Future Medicinal Chemistry

Volumn 2, Issue 4, 2010, Pages 575-586

  Steri, Ramona ^a   Kara, Mahmut ^a   Proschak, Ewgenij ^a   Steinhilber, Dieter ^a   Schneider, Gisbert ^a,b   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FARNESOID X RECEPTOR; GLIBENCLAMIDE; GLIMEPIRIDE; LIGAND; SULFONYLUREA DERIVATIVE;

ANIMAL CELL; ARTICLE; ASSAY; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIMULATION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GENES, REPORTER; GLYBURIDE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SULFONYLUREA COMPOUNDS; TRANSCRIPTIONAL ACTIVATION;

EID: 77953420997     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.10     Document Type: Article

References (34)

1. Rendell M. The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs 64(12), 1339-1358 (2004).
2. Müller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res. Clin. Pract. 28(Suppl.), 115-137 (1995).
3. Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13(9), 1135-1148 (2004).
4. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25(10), 2020-2030 (2005).
5. Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. 17, 139-159 (2010).
6. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor a gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17(2), 259-272 (2003).
7. Stayrook KR, Bramlett KS, Savkur RS et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146(3), 984-991 (2005).
8. Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25(3), 252-259 (2009).
9. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res. 49(2), 171-185 (2009).
10. Maloney PR, Parks DJ, Haffner CD et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43(16), 2971-2974 (2000).
11. Pellicciari R, Fiorucci S, Camaioni E et al. 6a-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45(17), 3569-3572 (2002).
12. Downes M, Verdecia MA, Roecker AJ et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11(4), 1079-1092 (2003).
13. Flatt B, Martin R, Wang TL et aAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. (2009).
14. Evans MJ, Mahaney PE, Borges-Marcucci L et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296(3), G543-G552 (2009).
15. Dussault I, Beard R, Lin M et al. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278(9), 7027-7033 (2003).
16. Kaimal R, Song X, Yan B, King R, Deng R. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones. J. Pharmacol. Exp. Ther. 330(1), 125-134 (2009).
17. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor g agonistic activity. J. Biol. Chem. 280(25), 23653-23659 (2005).
18. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using gold. Proteins 52(4), 609-623 (2003).
19. Eldridge MD, Murray CW, Auton TR, Paolini GY, Mee RP. Empirical scoring functions. I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11(5), 425-445 (1997).
20. Labute P. Protonate 3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 75(1), 187-205 (2009).
21. Case DA, Cheatham TE 3rd, Darden T et al. The amber biomolecular simulation programs. J. Comput. Chem. 26(16), 1668-1688 (2005).
22. Akwabi-Ameyaw A, Bass JY, Caldwell RD et al. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW4064. Bioorg. Med. Chem. Lett. 18(15), 4339-4343 (2008).
23. Allen T, Zhang F, Moodie SA et al. Halofenate is a selective peroxisome proliferator-activated receptor g modulator with antidiabetic activity. Diabetes 55(9), 2523-2533 (2006).
24. Goodwin B, Jones SA, Price RR et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and lRH-1 represses bile acid biosynthesis. Mol. Cell 6(3), 517-526 (2000).
25. Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7a-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275(15), 10918-10924 (2000)
26. Holt JA, Luo G, Billin AN et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17(13), 1581-1591 (2003).
27. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/ bile acid receptor. J. Biol. Chem. 276(31), 28857-28865 (2001).
28. Warnmark A, Treuter E, Wright AP, Gustafsson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol. Endocrinol. 17(10), 1901-1909 (2003).
29. Soisson SM, Parthasarathy G, Adams AD et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl Acad. Sci. USA 105(14), 5337-5342 (2008).
30. Feng S, Yang M, Zhang Z et al. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg. Med. Chem. Lett. 19, 2595-2598 (2009).
31. Akwabi-Ameyaw A, Bass JY, Caldwell RD et al. FXR agonist activity of conformationally constrained analogs of GW4064. Bioorg. Med. Chem. Lett. 19(16), 4733-4739 (2009).
32. Bass JY, Caldwell RD, Caravella JA et al. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bioorg. Med. Chem. Lett. 19(11), 2969-2973 (2009).
33. Nettles KW, Greene GL. Nuclear receptor ligands and cofactor recruitment: is there a coactivator 'on deck'? Mol. Cell 11(4), 850-851 (2003).
34. Lindblad U, Melander A. Sulphonylurea dose-response relationships: relation to clinical practice. Diabetes Obes. Metab. 2(1), 25-31 (2000).